Ieuan Clay, Nele Peerenboom, Dana E Connors, Steven Bourke, Alison Keogh, Katarzyna Wac, Tova Gur-Arie, Justin Baker, Christopher Bull, Andrea Cereatti, Francesca Cormack, Damien Eggenspieler, Luca Foschini, Raluca Ganea, Peter M A Groenen, Nicole Gusset, Elena Izmailova, Christoph M Kanzler, Lada Leyens, Kate Lyden, Arne Mueller, Julian Nam, Wan-Fai Ng, David Nobbs, Foteini Orfaniotou, Thanneer Malai Perumal, Wojciech Piwko, Anja Ries, Alf Scotland, Nick Taptiklis, John Torous, Beatrix Vereijken, Shuai Xu, Laurenz Baltzer, Thorsten Vetter, Jörg Goldhahn, Steven C Hoffmann
{"title":"数字措施的逆向工程:邀请患者参与对话。","authors":"Ieuan Clay, Nele Peerenboom, Dana E Connors, Steven Bourke, Alison Keogh, Katarzyna Wac, Tova Gur-Arie, Justin Baker, Christopher Bull, Andrea Cereatti, Francesca Cormack, Damien Eggenspieler, Luca Foschini, Raluca Ganea, Peter M A Groenen, Nicole Gusset, Elena Izmailova, Christoph M Kanzler, Lada Leyens, Kate Lyden, Arne Mueller, Julian Nam, Wan-Fai Ng, David Nobbs, Foteini Orfaniotou, Thanneer Malai Perumal, Wojciech Piwko, Anja Ries, Alf Scotland, Nick Taptiklis, John Torous, Beatrix Vereijken, Shuai Xu, Laurenz Baltzer, Thorsten Vetter, Jörg Goldhahn, Steven C Hoffmann","doi":"10.1159/000530413","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures.</p><p><strong>Summary: </strong>In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled \"Reverse Engineering of Digital Measures,\" was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools.</p><p><strong>Key messages: </strong>In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.</p>","PeriodicalId":11242,"journal":{"name":"Digital Biomarkers","volume":"7 1","pages":"28-44"},"PeriodicalIF":0.0000,"publicationDate":"2023-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189241/pdf/","citationCount":"2","resultStr":"{\"title\":\"Reverse Engineering of Digital Measures: Inviting Patients to the Conversation.\",\"authors\":\"Ieuan Clay, Nele Peerenboom, Dana E Connors, Steven Bourke, Alison Keogh, Katarzyna Wac, Tova Gur-Arie, Justin Baker, Christopher Bull, Andrea Cereatti, Francesca Cormack, Damien Eggenspieler, Luca Foschini, Raluca Ganea, Peter M A Groenen, Nicole Gusset, Elena Izmailova, Christoph M Kanzler, Lada Leyens, Kate Lyden, Arne Mueller, Julian Nam, Wan-Fai Ng, David Nobbs, Foteini Orfaniotou, Thanneer Malai Perumal, Wojciech Piwko, Anja Ries, Alf Scotland, Nick Taptiklis, John Torous, Beatrix Vereijken, Shuai Xu, Laurenz Baltzer, Thorsten Vetter, Jörg Goldhahn, Steven C Hoffmann\",\"doi\":\"10.1159/000530413\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures.</p><p><strong>Summary: </strong>In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled \\\"Reverse Engineering of Digital Measures,\\\" was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools.</p><p><strong>Key messages: </strong>In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.</p>\",\"PeriodicalId\":11242,\"journal\":{\"name\":\"Digital Biomarkers\",\"volume\":\"7 1\",\"pages\":\"28-44\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2023-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10189241/pdf/\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Digital Biomarkers\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1159/000530413\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2023/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"Computer Science\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Digital Biomarkers","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1159/000530413","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"Computer Science","Score":null,"Total":0}
引用次数: 2
摘要
背景:数字测量提供了一个无与伦比的机会,可以更全面地了解患者在真实世界环境中的行为,从而在患者、护理人员和用于推动药物开发和疾病管理的临床证据之间建立更好的联系。要实现这一愿景,就需要设计、开发、使用和决策的利益相关者利用数字测量的证据,将共同创造提高到一个新的水平。摘要:2022年9月,由瑞士苏黎世联邦理工学院(Swiss Federal Institute of Technology in Zürich)、美国国立卫生研究院生物标志物联盟基金会(Foundation for the National Institutes of Health Biomarkers Consortium)主办、威康信托基金会(Wellcome Trust)赞助的题为 "数字测量的逆向工程"(Reverse Engineering of Digital Measures)的系列会议的第二次会议在瑞士苏黎世举行,众多利益相关者分享了他们在四个案例研究中的经验,探讨了以患者为中心如何对数字证据生成工具的开发和验证至关重要:在本文中,我们讨论了在临床开发和护理服务中广泛使用数字措施生成证据的进展和仍然存在的障碍。我们还介绍了关键的讨论要点和收获,以便继续开展讨论,并为向更广泛的社区和其他利益相关者传播和推广提供基础。本文介绍的工作为我们提供了一个蓝图,说明如何以及为什么可以将患者的声音深思熟虑地融入到数字测量开发中,而且持续的多方参与对于取得进一步进展至关重要。
Reverse Engineering of Digital Measures: Inviting Patients to the Conversation.
Background: Digital measures offer an unparalleled opportunity to create a more holistic picture of how people who are patients behave in their real-world environments, thereby establishing a better connection between patients, caregivers, and the clinical evidence used to drive drug development and disease management. Reaching this vision will require achieving a new level of co-creation between the stakeholders who design, develop, use, and make decisions using evidence from digital measures.
Summary: In September 2022, the second in a series of meetings hosted by the Swiss Federal Institute of Technology in Zürich, the Foundation for the National Institutes of Health Biomarkers Consortium, and sponsored by Wellcome Trust, entitled "Reverse Engineering of Digital Measures," was held in Zurich, Switzerland, with a broad range of stakeholders sharing their experience across four case studies to examine how patient centricity is essential in shaping development and validation of digital evidence generation tools.
Key messages: In this paper, we discuss progress and the remaining barriers to widespread use of digital measures for evidence generation in clinical development and care delivery. We also present key discussion points and takeaways in order to continue discourse and provide a basis for dissemination and outreach to the wider community and other stakeholders. The work presented here shows us a blueprint for how and why the patient voice can be thoughtfully integrated into digital measure development and that continued multistakeholder engagement is critical for further progress.